| Biomarker ID | 1572 |
| PMID | 31059955 |
| Year | 2019 |
| Biomarker | Glucose Transporter 1 (GLUT1) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | increased with decreased BRFS |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 2.36 (95%CI 1.39 - 4.01) |
| Effect on Pathways | Pathway include: Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds; Metabolism of water-soluble vitamins and cofactors; Blood-Brain Barrier and Immune Cell Transmigration: Pathways Overview; Hexose transport; Integration of energy metabolism |
| Experiment | Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival |
| Type of Biomarker | Prognostic |
| Cohort | atients entered into a phase 3 randomised controlled trial of patients receiving EBRT (external beam radiotherapy) or EBRT (n=108) + HDR-BTb (n=110) (high-dose-rate brachytherapy boost). 204 samples were available after immunohistochemistry |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p < 0.001 |
| Method Used | Immunohistochemistry |
| Clinical | Yes |
| Remarks | NA |
| Clinical Trial Number | ISRCTN NO: ISRCTN98241100 |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |